BFM
ABOS icon

Boothbay Fund Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Boothbay Fund Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729K Hold
273,012
– – 0.01% 1281
2026
Q1 		$644K Buy
273,012
+233,427
+590% +$595K 0.01% 1198
2025
Q4 		$83.5K Sell
39,585
-11,457
-22% -$22.7K ﹤0.01% 1766
2025
Q3 		$87.3K Hold
51,042
– – ﹤0.01% 1743
2025
Q2 		$59.2K Hold
51,042
– – ﹤0.01% 1341
2025
Q1 		$56.1K Hold
51,042
– – ﹤0.01% 1275
2024
Q4 		$87.8K Sell
51,042
-666
-1% -$1.6K ﹤0.01% 1305
2024
Q3 		$128K Sell
51,708
-33,750
-39% -$91.6K ﹤0.01% 1430
2024
Q2 		$207K Buy
85,458
+33,750
+65% +$107K ﹤0.01% 1279
2024
Q1 		$209K Sell
51,708
-30,474
-37% -$115K ﹤0.01% 1324
2023
Q4 		$316K Buy
82,182
+20,997
+34% +$62.3K 0.01% 1168
2023
Q3 		$254K Sell
61,185
-65,921
-52% -$407K 0.01% 1331
2023
Q2 		$611K Buy
127,106
+62,580
+97% +$300K 0.01% 1012
2023
Q1 		$262K Buy
64,526
+1,611
+3% +$8.41K 0.01% 1588
2022
Q4 		$340K Buy
62,915
+335
+0.5% +$2.25K 0.01% 1330
2022
Q3 		$628K Buy
62,580
+49,853
+392% +$286K 0.02% 1107
2022
Q2 		$60K Buy
+12,727
New +$47.8K ﹤0.01% 2060

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management's ABOS Position: Q2 2026 in Review

Boothbay Fund Management held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 273,012 shares worth $729K. The position accounts for 0.01% of the portfolio, ranked #1281.

Boothbay Fund Management first reported a position in ABOS in Q2 2022 and has held it in 17 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Boothbay Fund Management held 273,012 shares of Acumen Pharmaceuticals worth $729K as of Q2 2026.
  • Boothbay Fund Management left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1281 holding.
  • Boothbay Fund Management first reported a position in Acumen Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.